Ctc-501

Depression, Bipolar

Region SkanePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Depression, Bipolar cohort.

Asset / Sponsor	Phase	Rating
Olanzapine China Medical University, China	Phase 4	BBB
ZIPRASIDONE Queen's University	Phase 4	BBB
Valproic Acid Ewha Womans University Mokdong Hospital	Phase 4	BB
Cariprazine Aalborg University Hospital	Phase 4	BB
Starch China Medical University, China	Phase 4	BB

View all 23 →

Same molecule, other indications

Ctc-501 is also rated in:

Parkinson diseaseDormant

BBB

Indicative ·

72 / 100

bipolar disorderDormant

BB

Indicative ·

68 / 100

adrenoleukodystrophyDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.